eligibility_summary
Ages 1–21 with Hodgkin or NHL. Procurement: >6-wk expectancy, Hgb ≥7, consent, exclude severe infection, active HIV/HBV/HCV, steroids, GVHD. Treatment: in CR but high risk (stage III/IV at dx, in CR2, >2 prior lines), adequate organs (bili/AST <3×ULN, Cr ≤2×ULN), Hgb ≥7, K/L >60, washouts: trials 1 mo, therapy ≥1 wk, RT ≥4 wks, contraception, exclude pregnancy/breastfeeding, steroids >0.5 mg/kg, active HIV/HBV/HCV, severe infection, GVHD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT05134740 (withdrawn): Phase 1, single-arm adoptive cell immunotherapy in pediatric Hodgkin and non-Hodgkin lymphoma at high relapse risk. Intervention: autologous tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs), a biological cell therapy generated ex vivo from patient blood and expanded to recognize NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX. Mechanism: TCR-mediated recognition of TAA peptides presented on HLA class I on lymphoma cells, triggering CTL cytotoxic killing (perforin/granzyme) and cytokine release to eliminate minimal residual disease and prevent relapse. Targets: lymphoma cells expressing the listed TAAs, key pathways include antigen processing/presentation (MHC I) and adaptive T-cell effector signaling. Primary aim: safety/tolerability.